Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 2 10Phase 3 8Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8CNS 7Sarcoma 4Breast 4Genitourinary 3Head & Neck 2Gynecologic 2

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 48Cyclophosphamide 33Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Surgical Procedures, Operative × Gynecologic × Clear all
NCT05081609 2026-02-24

IL Believe

Ascendis Pharma A/S

Phase 1/2 Active not recruiting
320 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT06602063 2025-06-27

Surgery for Relapsed Ovarian Cancer in Precision

Shanghai Gynecologic Oncology Group

Phase 1/2 Not yet recruiting
33 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡